MENU
+Compare
AQST
Stock ticker: NASDAQ
AS OF
Aug 22 closing price
Price
$3.98
Change
+$0.07 (+1.79%)
Capitalization
481.48M

AQST Aquestive Therapeutics Forecast, Technical & Fundamental Analysis

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs... Show more

AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for AQST with price predictions
Aug 22, 2025

AQST sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for AQST moved above the 200-day moving average on August 01, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 22, 2025. You may want to consider a long position or call options on AQST as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AQST advanced for three days, in of 261 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for AQST moved out of overbought territory on July 22, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 similar instances where the indicator moved out of overbought territory. In of the 32 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 48 cases where AQST's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for AQST turned negative on July 25, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AQST declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AQST broke above its upper Bollinger Band on August 14, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for AQST entered a downward trend on August 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (16.184). P/E Ratio (0.000) is within average values for comparable stocks, (73.424). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.049). AQST has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (8.503) is also within normal values, averaging (41.240).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AQST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AQST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.

View a ticker or compare two or three
AQST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

AQST is expected to report earnings to rise 9.50% to -15 cents per share on November 10

Aquestive Therapeutics AQST Stock Earnings Reports
Q3'25
Est.
$-0.15
Q2'25
Beat
by $0.03
Q1'25
Missed
by $0.08
Q4'24
Missed
by $0.06
Q3'24
Missed
by $0.01
The last earnings report on August 11 showed earnings per share of -14 cents, beating the estimate of -17 cents. With 1.14M shares outstanding, the current market capitalization sits at 481.48M.
A.I. Advisor
published General Information

General Information

a developer thin film pharmaceutical and over the counter drug products

Industry PharmaceuticalsGeneric

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
30 Technology Drive
Phone
+1 908 941-1900
Employees
135
Web
https://www.aquestive.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BMPSX96.702.71
+2.88%
ProFunds Materials UltraSector Svc
PGTYX82.551.43
+1.76%
Putnam Global Technology Y
DFMIX36.840.58
+1.60%
Davidson Multi-Cap Equity I
PWCIX88.861.19
+1.36%
Principal Capital Appreciation Inst
DRTHX20.920.25
+1.21%
BNY Mellon Sustainable US Eq Fd Z

AQST and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, AQST has been loosely correlated with HROW. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if AQST jumps, then HROW could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AQST
1D Price
Change %
AQST100%
+1.79%
HROW - AQST
33%
Loosely correlated
+2.52%
ESPR - AQST
32%
Poorly correlated
+1.88%
BCRX - AQST
30%
Poorly correlated
+2.15%
SCYX - AQST
30%
Poorly correlated
+0.21%
SBFM - AQST
28%
Poorly correlated
-1.41%
More

Groups containing AQST

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AQST
1D Price
Change %
AQST100%
+1.79%
Pharmaceuticals: Generic
industry (225 stocks)
21%
Poorly correlated
+1.06%